About: Razelle Kurzrock

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Razelle Kurzrock Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідниця (uk) эрдэмтэн (mn) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtuese (sq) ricercatrice (it)
rdfs:label	Razelle Kurzrock (en) Razelle Kurzrock (es) Razelle Kurzrock (nl) Razelle Kurzrock (ast)
skos:prefLabel	Razelle Kurzrock (en) Razelle Kurzrock (es) Razelle Kurzrock (nl) Razelle Kurzrock (ast)
name	Razelle Kurzrock (en) Razelle Kurzrock (es) Razelle Kurzrock (nl) Razelle Kurzrock (ast)
instance of	wds:Q56614941-CF8C81EF-9FF6-4EAD-96FB-F54F7E717180
instance of	Homo sapiens
Nationale Thesaurus voor Auteursnamen ID	wds:Q56614941-2efe3221-31a9-4c0c-807d-be385b4a1f06
occupation	wds:Q56614941-17D97244-92F7-4B6C-AF5C-1EA61E0F6603
employer	wds:Q56614941-ae963740-4ace-a4e3-7d4a-8385ed7b698e
NUKAT ID	wds:Q56614941-454529BE-69A3-464B-89F6-7FF4C09F1233
X username	wds:Q56614941-d4011710-434d-1cca-7a2b-13d2d5e98917
sex or gender	wds:Q56614941-4b2e6152-40c1-5c96-ff25-ab30998cb02b
VIAF ID	wds:Q56614941-B1E5006B-0DDA-4F11-9E8A-FA3D820A797F
GND ID	wds:Q56614941-30adc0be-7964-491b-8e1c-cacb29a5c39c
Library of Congress authority ID	wds:Q56614941-0A9DD8A6-94B0-449B-9536-5D3F1ABA450E
Prabook ID	wds:Q56614941-7B49B5F4-5509-4F11-9ED9-13B84602056F
date of birth	wds:Q56614941-AF8F5C75-21EC-4C90-91EF-72EB16A4E4F2
WorldCat Identities ID (superseded)	wds:Q56614941-9CA07901-0CD5-496C-B6E3-78FE06A8711B
National Library of Israel J9U ID	wds:Q56614941-4229D8ED-1C7E-4170-92E8-7C569D01F7B7
social media followers	wds:Q56614941-5c574ac8-9c74-440d-adf7-d6959ebfef1e wds:Q56614941-82f69a2f-d0c3-4989-bca4-320934b5426f
Nationale Thesaurus voor Auteursnamen ID	http://data.bibliotheken.nl/id/thes/p145996743
VIAF ID	http://viaf.org/viaf/241332384
GND ID	https://d-nb.info/gnd/134284496
Library of Congress authority ID	http://id.loc.gov/authorities/names/n92800469
Nationale Thesaurus voor Auteursnamen ID	145996743
occupation	researcher
employer	University of California, San Diego
NUKAT ID	n2003066135
X username	Dr_R_Kurzrock
sex or gender	female organism
VIAF ID	241332384
GND ID	134284496
Library of Congress authority ID	n92800469
Prabook ID	3436676
date of birth	1954-01-01 00:00:00Z (xsd:dateTime)
WorldCat Identities ID (superseded)	lccn-n92800469
National Library of Israel J9U ID	987007445311505171
social media followers	3478 (xsd:decimal)
ORCID iD	wds:Q56614941-670653C5-36A5-4FF2-AE2F-CF4223FA77C9
ORCID iD	https://orcid.org/0000-0003-4110-1214
ORCID iD	0000-0003-4110-1214
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56614941
is author of	Phase II trial of curcumin in patients with advanced pancreatic cancer Novel therapeutic targets in non-small cell lung cancer Epstein-Barr virus and cancer Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics Sarcoidosis and malignancy Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors A phase I clinical trial of darinaparsin in patients with refractory solid tumors. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers Molecular tumor board: the University of California-San Diego Moores Cancer Center experience KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software